The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine
This educational activity is based from a live satellite symposium from the 38th European Cystic Fibrosis Conference held in Brussels, Belgium. The expert faculty for this CME activity will present a comprehensive review of the effects of CFTR modulation therapeutics on cystic fibrosis disease progression. The new era of precision medicine has arrived and many patients can now be managed on the basis of phenotypes where very good healthcare outcomes can be achieved. Cystic fibrosis patients on treatment show new progress on lung function, BMI, exercise ability, infectious complications, life expectancy, co-morbid conditions such as diabetes, liver failure, bone disease, and overall quality of life. This clinically relevant activity also includes panel discussions with case presentations to advance your skills in caring for cystic fibrosis patients.
Pulmonologists, pediatricians, infectious disease, and other healthcare clinicians responsible for the care of patients with cystic fibrosis.
Upon completion of this activity, participants will be able to:
- Review the principles of precision medicine as it pertains to CFTR modulation therapeutics.
- Recognize risk factors and predictors of disease progression in the patient with cystic fibrosis.
- Evaluate the impact of CFTR modulation therapeutics on disease progression in the patient with cystic fibrosis.
- Describe current approaches to effectively manage patients on CFTR modulation therapeutics.
J. Stuart Elborn, MD
Jane Davies, MD
Scott Bell, MD
Nico Derichs, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Relationship Identified With:
J. Stuart Elborn, MD
Consultant/Advisor: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation
Speaker’s Bureau: Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated
Jane Davies, MD
Consultant/Advisor: Forest Laboratories, Inc.; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Proteostasis Therapeutics; Pulmocide Ltd; Verona Pharma plc; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Novartis Pharmaceuticals Corporation
Speaker's Bureau: Forest Laboratories, Inc.; Vertex Pharmaceuticals Incorporated
Scott Bell, MD
Consultant/Advisor: PTC Therapeutics; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated
Speaker’s Bureau: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated
|Nico Derichs, MD|
Consultant/Advisor: Bayer Pharma AG
Grant/Research Support: Bayer Pharma AG; Vertex Pharmaceuticals Incorporated
Planners, Managers, Reviewers: Sandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Stephanie Breslan and Bernard Abrams, MD, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.
Co-provided by the Elsevier Office of Continuing Medical Education, Dannemiller and AcademicCME.
Course Open Date: August 21, 2015 | Course Expiration Date: August 20, 2016
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses)
Dannemiller is a provider approved by the California Board of Registered Nursing (CBRN), Provider Number 4229. This activity has been approved for 2.0 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, DanneMiller, AcademicCME, and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.